We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+47.97%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.08B
AUM Growth
+$374M
Cap. Flow
+$212M
Cap. Flow %
19.62%
Top 10 Hldgs %
41.77%
Holding
136
New
30
Increased
24
Reduced
21
Closed
13

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.5M
2
LIAN
LianBio American Depositary Shares
LIAN
+$26M
3
OKUR
OnKure Therapeutics
OKUR
+$20.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$20.6M
5
VTYX
Ventyx Biosciences
VTYX
+$19M

Top Sells

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$22.4M
2
THRD
Third Harmonic Bio
THRD
+$11.5M
3
NVCR icon
NovoCure
NVCR
+$7.95M
4
BLUE
bluebird bio
BLUE
+$7.87M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.79M

Sector Composition

Rank Sector Weight
1 Healthcare 95.77%
2 Financials 3.5%
3 Real Estate 0.65%
4 Technology 0.08%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
76
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.17M 0.29%
10,000
– –
HRTX icon
77
Heron Therapeutics
HRTX
$92.9M
$3.15M 0.29%
1,850,000
– –
IFRX icon
78
InflaRx
IFRX
$271M
$3.05M 0.28%
1,873,753
-950,600
-34% -$1.63M
AMLX icon
79
Amylyx Pharmaceuticals
AMLX
$2.54B
$2.94M 0.27%
+200,000
New +$3.07M
ENTA icon
80
Enanta Pharmaceuticals
ENTA
$400M
$2.82M 0.26%
+300,000
New +$2.8M
LONA
81
LeonaBio Inc
LONA
$72.1M
$2.8M 0.26%
115,272
+80,000
+227% +$1.42M
AMRN
82
Amarin Corp
AMRN
$303M
$2.69M 0.25%
154,327
-138,799
-47% -$2.18M
FATE icon
83
Fate Therapeutics
FATE
$326M
$2.62M 0.24%
700,000
– –
MCRB icon
84
Seres Therapeutics
MCRB
$48.4M
$2.51M 0.23%
+89,644
New +$2.35M
PASG icon
85
Passage Bio
PASG
$14.1M
$2.42M 0.22%
120,000
+100,000
+500% +$1.38M
ENZ
86
DELISTED
Enzo Biochem, Inc.
ENZ
$2.36M 0.22%
1,700,000
-500,000
-23% -$663K
BLUE
87
DELISTED
bluebird bio
BLUE
$2.35M 0.22%
85,000
-129,141
-60% -$7.87M
SPRY icon
88
ARS Pharmaceuticals
SPRY
$612M
$2.24M 0.21%
409,463
– –
EDIT icon
89
Editas Medicine
EDIT
$442M
$2.03M 0.19%
200,000
– –
SFBS
90
ServisFirst Bancshares
SFBS
$4.86B
$2M 0.18%
30,000
– –
PDSB icon
91
PDS Biotechnology
PDSB
$43.4M
$1.99M 0.18%
400,000
– –
TNGX icon
92
Tango Therapeutics
TNGX
$4.41B
$1.98M 0.18%
200,000
– –
ELEV
93
DELISTED
Elevation Oncology
ELEV
$1.97M 0.18%
3,667,600
-332,400
-8% -$176K
LITS
94
Lite Strategy Inc
LITS
$30.9M
$1.89M 0.17%
326,084
– –
GNFT
95
DELISTED
Genfit
GNFT
$1.85M 0.17%
479,441
-561,195
-54% -$1.86M
ACRS icon
96
Aclaris Therapeutics
ACRS
$869M
$1.84M 0.17%
+1,753,335
New +$5.35M
TGTX icon
97
TG Therapeutics
TGTX
$7.62B
$1.71M 0.16%
100,000
– –
ACET icon
98
Adicet Bio
ACET
$74.7M
$1.66M 0.15%
54,772
-21,875
-29% -$477K
ALGS icon
99
Aligos Therapeutics
ALGS
$34.9M
$1.45M 0.13%
87,594
-45,568
-34% -$783K
LVTX
100
DELISTED
LAVA Therapeutics
LVTX
$1.33M 0.12%
+840,593
New +$1.2M
2 3
4
5 6

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Tang Capital Management held 136 positions worth $1.08B, up 53% from $709M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tang Capital Management deployed $212M of net new capital in Q4 2023, opening 30 new positions and adding to 24 existing holdings. Its largest new stake was OnKure Therapeutics: 333,000 shares worth $5.33M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was bluebird bio, an estimated $7.87M trimmed.

  • Tang Capital Management's largest Q4 2023 buy was OnKure Therapeutics: 333,000 shares worth $5.33M.
  • Tang Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $77.5M increase.
  • Tang Capital Management's biggest Q4 2023 reduction was bluebird bio, cutting an estimated $7.87M.
  • Tang Capital Management fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $22.4M.
  • Tang Capital Management's ten largest holdings make up 42% of its $1.08B portfolio in Q4 2023.
  • Tang Capital Management opened 30 new positions and closed 13 in Q4 2023.
  • Tang Capital Management's portfolio value rose 53% quarter-over-quarter to $1.08B.

Based on Tang Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.